Acologix Presents In Vivo Results on AC-100 at the American Society for Bone and Mineral Research Annual Meeting

Emeryville, CA-October 4, 2004 — Acologix, Inc., a privately held biopharmaceutical company, today presented data from in vivo preclinical studies of its lead compound, AC-100, during the 26th Annual Meeting of the American Society for Bone and Mineral Research, being held in Seattle, Washington, USA. The presentation entitled “AC-100, a Fragment of MEPE, Promotes Fracture Healing in a Femoral Closed Fracture Model in Rats,” abstract # 1775, was presented by Mirella Lazarov, DDS, Ph.D., Acologix Senior Scientist, Preclinical Development. The data suggest that AC-100 promotes fracture healing in an experimental model and may have potential as an anabolic drug to increase bone mass.

AC-100, a synthetic peptide, is being developed for indications related to bone and dentin regeneration. In several in vitro and in vivo preclinical models, AC-100 has demonstrated potent and selective bone formation activities that were superior, or similar, to other known skeletal growth and differentiation factors.

“The clinical development for AC-100 is targeted initially for local bone and dentin regeneration with other possible applications for acute treatment of osteoporosis,” said Mr. Yoshi Kumagai, Acologix’ President and Chief Executive Officer.

A Phase I clinical study in healthy volunteers, completed in 2003, demonstrated a very favorable safety profile and that the drug was well tolerated.

Most of the current therapeutics on the market or those under development for osteoporosis are preventive drugs which simply delay advancement of bone loss. No molecule that can regenerate dentin tissues is known to date. In the U.S. today, it is estimated that 10 million individuals have osteoporosis and almost 34 million are estimated to have low bone mass, placing them at increased risk for osteoporosis.

About Acologix, Inc.

Acologix Inc., based in Emeryville, Calif., is a privately held biopharmaceutical company focused on developing and commercializing novel therapeutics primarily for the treatment of metabolic disorders of kidney and bone that represent significant unmet medical needs. Founded in 1992, the Company’s research and development efforts are centered on the body’s metabolism of minerals and extracellular matrix molecules. This has led to the identification of unique therapeutic candidates for product development and commercialization. Acologix is seeking strategic development, commercial partnerships and licensees with pharmaceutical and biotechnology companies for several of its programs.

This press release contains “forward-looking” statements. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements include statements regarding product development and cannot be guaranteed. Acologix undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Acologix’s business.

Company Contact

Yoshi Kumagai
President & CEO
Phone: 510.379.1073 ext 10
Fax: 510.379.1074